

# **Induction of specific adaptive immune responses by immunization with newly designed artificial glycosphingolipids**

Tetsuya Okuda<sup>1\*</sup>, Kayoko Shimizu<sup>2</sup>, Satoshi Hasaba<sup>2</sup>, Mutsuhiro Date<sup>2</sup>

1. Bio-Design Research Group, Bioproduction Research Institute, National Institute of Advanced Industrial Science and Technology (AIST), Central 6, 1-1-1 Higashi, Tsukuba, Japan

2. Diagnostics Research Laboratories, Diagnostics Technical Service & Research Operations, Diagnostics Division, FUJIFILM Wako Pure Chemical Corporation, 6-1 Takada, Amagasaki, Hyogo, Japan.

## **Supplementary Information**


Supplemental Figure S1

Supplemental Figure S2


Supplemental Figure S3

Supplemental Figure S4


Supplemental Figure S5




**Figure S1.** Anti-immunogen IgG titers in diluted sera from CF4-C12L or CF4-C182L immunized mice. The D7 sera of mice with high antibody titer in Fig. 5 were analyzed (n=3). The *open circles*, *open squares*, and *closed triangle* indicate the serum from individual mouse. Serum IgG titers against each immunogen were determined by ELISA as described in the *Methods*.





**Figure S2.** Titers of immunogen-specific serum antibodies in  $\alpha$ GalCer-immunized mice. Mice were immunized with  $\alpha$ GalCer, and serum was prepared 7 days (*gray bars*) after the final immunization. *Closed bars*, serum from non-treated mice. Titers of serum IgM (*upper panel*) and IgG (*lower panel*) against  $\alpha$ GalCer were determined by ELISA. Titers of immunogen-specific serum antibodies in CF4-C12L– and CF4-C182L–immunized mice are shown for reference. Error bars: mean  $\pm$  S.D. (n = 4-7). \* $P < 0.05$ , \*\* $P < 0.01$ , \*\*\* $P < 0.001$  BG vs. D7.



**Figure S3.** Serum antibody titers in mice repetitively immunized with CF4 conjugates. Serum of mice immunized more than 4 times with CF4-C12L (*closed squares with solid line*) or CF4-C182L (*open circles with dotted line*) was prepared 3 days after the final immunization (4<sup>th</sup>). Titers of serum IgG against each immunogen were determined by ELISA. BG, serum from non-treated mice; 2<sup>nd</sup>, serum from second booster immunization. Error bars: mean  $\pm$  S.D. (n = 3-4). \*\* $P < 0.01$  anti-CF4-C12L vs. anti-CF4-C182L.



**Figure S4.** Serum immunoglobulin isotypes in CF4-C12L–immunized mice. A mouse (No. 3 in Fig. 8) was repetitively immunized with CF4-C12L, and serum was prepared 3 days after the final immunization. Figure shows serum immunoglobulin isotypes determined using a mouse antibody isotyping kit.



**Figure S5.** Immobilization efficiency of artificial glycolipid on microtiter plate. A 96-well microtiter plate was coated with 500 ng of several derivatives of ceramide portion of the 6'-sialyl LacNAc-C12L. Immobilized efficiency was determined by binding of an anti-6'-sialyl LacNAc antibody FR9 as described in the *Methods*. BG: absorbance of uncoated wells. Error bars: mean  $\pm$  S.D. (n = 3).